With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.
DCell, a visible neural network, uses deep learning techniques to model cellular behavior almost as accurately as has been observed in laboratory settings.
Using RNA sequences for thousands of cells, researchers looked at head and neck squamous cell carcinomas and proposed streamlined expression subtypes.
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
Foundation Medicine's SmartTrials Precision Enrollment program will ID patients with HRAS mutant squamous cell carcinoma of the head and neck.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
A subset of mutation-associated neoantigens appeared to be lost from lung or head and neck tumors that became resistant to anti-PD1 or anti-PD1 and anti-CLTA4 therapy.
Spokespersons from Bio-Rad noted that there appears to be an increasing number of researchers using ddPCR for methylation analyses.
Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.
The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.
Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.
In Nature this week: ash dieback disease fungal genome, and more.